Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines and Revolution Medicines have announced a collaboration to develop and commercialize oncology therapies. This partnership includes a clinical collaboration to evaluate drug combinations with select oncology assets from BeOne. The focus is on targeted therapies for patients suffering from RAS-addicted cancers, indicating a strategic alignment in oncology development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to enhance clinical development.
  • Combining resources may lead to innovative therapies.
  • Focus on RAS-addicted cancers shows targeted approach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
lenvatinib
Phase 2 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution

Frequently Asked Questions

What companies are involved in the collaboration?

The collaboration involves BeOne Medicines and Revolution Medicines.

What is the focus of the collaboration?

The collaboration focuses on developing targeted therapies for RAS-addicted cancers.

What type of collaboration is announced?

A clinical collaboration to evaluate drug combinations is announced.

Where are the companies based?

BeOne Medicines is based in San Carlos, and Revolution Medicines in Redwood City, California.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines Revolution Medicines oncology RAS-addicted cancers clinical development
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
lenvatinibPhase 2
Advanced Solid Tumor →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →